کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2929934 | 1576245 | 2012 | 8 صفحه PDF | دانلود رایگان |
BackgroundWe tested the effects of rosuvastatin combined with ramipril on atheroma volume and its mechanism in de novo, intermediate coronary artery disease.MethodsSubjects were randomly assigned to 2 treatment groups (rosuvastatin alone group; 20 mg/day, combined group; rosuvastatin 20 mg/day and ramipril 10 mg/day). Total atheroma volume per 10 mm segment (TAV/10 mm), percent atheroma volume per 10 mm segment (PAV/10 mm) in entire indexed segments and TAVmost10, PAVmost10 in a 10 mm subsegment with the greatest disease by intravascular ultrasound, and lipids, metabolic parameters (adiponectin, insulin sensitivity), biomarkers (hsCRP, matrix metalloproteinase-9) were analyzed at baseline and at 9–12 months follow-up.ResultsA total of 40 patients (rosuvastatin group; 21, combined group; 19), 46 lesions (rosuvastatin group; 24, combined group; 22) were finally analyzed. Rosuvastatin alone significantly reduced TAV/10 mm (− 7.8 ± 17.4%, p < 0.001) but did not change PAV/10 mm, TAVmost10, PAVmost10 after therapy. In combined group, TAV/10 mm, TAVmost10, PAVmost10 were significantly reduced after therapy (− 10.7 ± 11.5%, − 13.4 ± 14.5%, − 2.7 ± 5.8%, p < 0.001, < 0.001 and p = 0.04) but PAV/10 mm did not change. The magnitude of changes of all IVUS derived parameters did not differ significantly between 2 groups. Of interest, the most important factor for the changes of PAVmost10 was the percent changes of LDL cholesterol (β = 0.23, 95% CI [0.07–0.39], p = 0.007) in rosuvastatin alone group and the changes in hsCRP (β = 1.89, 95% CI [0.63–3.14], p = 0.005) and baseline fasting blood glucose (β = 0.06, 95% CI [0.01–0.11], p = 0.02) in combined group by multivariate analysis.ConclusionsRosuvastatin combined ramipril therapy significantly reduced atheroma volume that was related with anti-inflammatory effects.
Journal: International Journal of Cardiology - Volume 158, Issue 2, 12 July 2012, Pages 217–224